Carbapenem Versus Fosfomycin Tromethanol in the Treatment of Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli-Related Complicated Lower Urinary Tract Infection

摘要: The aim of this observational prospective study was to compare the effect fosfomycin tromethanol (FT) and carbapenems (meropenem or imipenem cilastatin) in treatment extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli-related complicated lower urinary tract infection (CLUTI). Inclusion criteria were: patients who were aged >18 yr with dysuria problems frequency urgency passing urine; those >20 leukocytes/mm³ urine microscopy culture-proven ESBL-producing carbapenem FT-sensitive E. coli (>10⁵ cfu/mm³); no leukocytosis fever; treated ft (oral 3 g sachet x 1 every other night, three times) between march 2005 January 2006 our outpatient clinic hospital. A total 47 CLUTI attacks (27 FT group, 20 group) observed prospectively. Clinical microbiological success groups similar (19/20 vs 21/27 16/20 16/27 p>0.05). Drug acquisition costs significantly group (p<0.001). Although it is not a randomized controlled study, these data show that may be suitable, effective cheap alternative CLUTI.